Atryn Purple Book BLA 125284

BLA number
125284
Proprietary names
Atryn
Proper names
Antithrombin (Recombinant)
Applicant
rEVO Biologics, Inc.
Center
CBER
First observed release
2020-08-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001AtrynAntithrombin (Recombinant)351(a)1750IUFor InjectionIntravenousSingle-Dose VialDiscVoluntarily Revoked2009-02-06
002AtrynAntithrombin (Recombinant)351(a)525IUFor InjectionIntravenousSingle-Dose VialDiscVoluntarily Revoked2014-04-11

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2023-04-01U001Atryn351(a)DiscrEVO Biologics, Inc.
2023-04-01U002Atryn351(a)DiscrEVO Biologics, Inc.
2021-09-01U001Atryn351(a)RxrEVO Biologics, Inc.
2021-09-01U002Atryn351(a)RxrEVO Biologics, Inc.
2021-05-01U001Atryn351(a)RxrEVO Biologics, Inc.
2021-05-01U002Atryn351(a)RxrEVO Biologics, Inc.
2020-08-01R001Atryn351(a)RxrEVO Biologics, Inc.
2020-08-01R002Atryn351(a)RxrEVO Biologics, Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2023-04-01001Atryn351(a)DiscVoluntarily Revoked2009-02-06
2023-04-01002Atryn351(a)DiscVoluntarily Revoked2014-04-11
2020-08-01001Atryn351(a)RxLicensed2009-02-06
2020-08-01002Atryn351(a)RxLicensed2014-04-11